Home > Oncology > ESMO 2019 > Lung Cancer > Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma

Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma

Expert
Dr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK
Conference
ESMO 2019
Trial
PROMISE-meso

Results from the PROMISE-meso study showed better response rates but no survival benefit in pretreated mesothelioma patients treated with pembrolizumab monotherapy compared with chemotherapy. Nonetheless, current results are encouraging and the results of investigations of checkpoint inhibitor treatments in earlier stage mesothelioma are eagerly awaited [1].

PROMISE-meso randomised 144 patients with advanced pre-treated mesothelioma to either immune checkpoint inhibitor pembrolizumab (200 mg every 3 weeks) or to investigators’ choice of standard chemotherapy (gemcitabine or vinorelbine). Patients in the control group were able to cross over to pembrolizumab at progression. Nearly 4 times more patients responded to immunotherapy. The objective response rate was 22% in patients with pembrolizumab compared with 6% with chemotherapy (P=0.004). Median progression-free survival was 2.5 months (95% CI 2.1 to 4.2) and 3.4 months (95% CI 2.2 to 4.3) respectively (P...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on